-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
The -X- _ O
development -X- _ O
of -X- _ O
a -X- _ O
protective -X- _ O
vaccine -X- _ O
against -X- _ O
canine -X- _ O
visceral -X- _ O
leishmaniasis -X- _ O
( -X- _ O
CVL -X- _ O
) -X- _ O
is -X- _ O
an -X- _ O
alternative -X- _ O
approach -X- _ O
for -X- _ O
interrupting -X- _ O
the -X- _ O
domestic -X- _ O
cycle -X- _ O
of -X- _ O
Leishmania -X- _ O
infantum. -X- _ O
Given -X- _ O
the -X- _ O
importance -X- _ O
of -X- _ O
sand -X- _ O
fly -X- _ O
salivary -X- _ O
proteins -X- _ O
as -X- _ O
potent -X- _ O
immunogens -X- _ O
obligatorily -X- _ O
co-deposited -X- _ O
during -X- _ O
transmission -X- _ O
of -X- _ O
Leishmania -X- _ O
parasites -X- _ O
, -X- _ O
their -X- _ O
inclusion -X- _ O
in -X- _ O
an -X- _ O
anti-Leishmania -X- _ O
vaccine -X- _ O
has -X- _ O
been -X- _ O
investigated -X- _ O
in -X- _ O
the -X- _ O
last -X- _ O
few -X- _ O
decades. -X- _ O
In -X- _ O
this -X- _ O
context -X- _ O
, -X- _ O
we -X- _ O
previously -X- _ O
immunized -X- _ B-Outcome
dogs -X- _ I-Outcome
with -X- _ B-Intervention
a -X- _ I-Intervention
vaccine -X- _ I-Intervention
composed -X- _ I-Intervention
of -X- _ I-Intervention
L. -X- _ I-Intervention
braziliensis -X- _ I-Intervention
antigens -X- _ I-Intervention
plus -X- _ I-Intervention
saponin -X- _ I-Intervention
as -X- _ I-Intervention
the -X- _ I-Intervention
adjuvant -X- _ I-Intervention
and -X- _ I-Intervention
sand -X- _ I-Intervention
fly -X- _ I-Intervention
salivary -X- _ I-Intervention
gland -X- _ I-Intervention
extract -X- _ I-Intervention
( -X- _ I-Intervention
LBSapSal -X- _ I-Intervention
vaccine -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
This -X- _ O
vaccine -X- _ O
elicited -X- _ O
an -X- _ O
increase -X- _ O
in -X- _ O
both -X- _ O
anti-saliva -X- _ O
and -X- _ O
anti- -X- _ O
Leishmania -X- _ O
IgG -X- _ O
isotypes -X- _ O
, -X- _ O
higher -X- _ O
counts -X- _ O
of -X- _ O
specific -X- _ O
circulating -X- _ O
CD8 -X- _ O
( -X- _ O
+ -X- _ O
) -X- _ O
T -X- _ O
cells -X- _ O
, -X- _ O
and -X- _ O
high -X- _ O
NO -X- _ O
production. -X- _ O
METHODS -X- _ O
: -X- _ O
We -X- _ O
investigated -X- _ O
the -X- _ O
immunogenicity -X- _ O
and -X- _ O
protective -X- _ O
effect -X- _ O
of -X- _ O
LBSapSal -X- _ B-Intervention
vaccination -X- _ I-Intervention
after -X- _ O
intradermal -X- _ O
challenge -X- _ O
with -X- _ O
1 -X- _ O
Ã— -X- _ O
10 -X- _ O
( -X- _ O
7 -X- _ O
) -X- _ O
late-log-phase -X- _ O
L. -X- _ O
infantum -X- _ O
promastigotes -X- _ O
in -X- _ O
the -X- _ O
presence -X- _ O
of -X- _ O
sand -X- _ O
fly -X- _ O
saliva -X- _ O
of -X- _ O
Lutzomyia -X- _ O
longipalpis. -X- _ O
The -X- _ O
dogs -X- _ O
were -X- _ O
followed -X- _ O
for -X- _ O
up -X- _ O
to -X- _ O
885 -X- _ O
days -X- _ O
after -X- _ O
challenge. -X- _ O
RESULTS -X- _ O
: -X- _ O
The -X- _ B-Outcome
LBSapSal -X- _ I-Outcome
vaccine -X- _ I-Outcome
presents -X- _ I-Outcome
extensive -X- _ I-Outcome
antigenic -X- _ I-Outcome
diversity -X- _ I-Outcome
with -X- _ I-Outcome
persistent -X- _ I-Outcome
humoral -X- _ I-Outcome
and -X- _ I-Outcome
cellular -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
, -X- _ I-Outcome
indicating -X- _ I-Outcome
resistance -X- _ I-Outcome
against -X- _ I-Outcome
CVL -X- _ I-Outcome
is -X- _ I-Outcome
triggered -X- _ I-Outcome
by -X- _ I-Outcome
high -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
total -X- _ I-Outcome
IgG -X- _ I-Outcome
and -X- _ I-Outcome
its -X- _ I-Outcome
subtypes -X- _ I-Outcome
( -X- _ I-Outcome
IgG1 -X- _ I-Outcome
and -X- _ I-Outcome
IgG2 -X- _ I-Outcome
) -X- _ I-Outcome
; -X- _ I-Outcome
expansion -X- _ I-Outcome
of -X- _ I-Outcome
circulating -X- _ I-Outcome
CD5 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
CD4 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
CD8 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
T -X- _ I-Outcome
lymphocytes -X- _ I-Outcome
and -X- _ I-Outcome
is -X- _ I-Outcome
Leishmania-specific -X- _ I-Outcome
; -X- _ I-Outcome
and -X- _ I-Outcome
reduction -X- _ I-Outcome
of -X- _ I-Outcome
splenic -X- _ I-Outcome
parasite -X- _ I-Outcome
load. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
These -X- _ O
results -X- _ O
encourage -X- _ O
further -X- _ O
study -X- _ O
of -X- _ O
vaccine -X- _ O
strategies -X- _ O
addressing -X- _ O
Leishmania -X- _ O
antigens -X- _ O
in -X- _ O
combination -X- _ O
with -X- _ O
proteins -X- _ O
present -X- _ O
in -X- _ O
the -X- _ O
saliva -X- _ O
of -X- _ O
the -X- _ O
vector -X- _ O
. -X- _ O

